CYP2C9 Variations and Their Pharmacogenetic Implications Among Diverse South Asian Populations
Open Access
- 1 January 2021
- journal article
- research article
- Published by Taylor & Francis in Pharmacogenomics and Personalized Medicine
- Vol. ume 14, 135-147
Abstract
Introduction: Allelic frequency distribution of drug metabolizing enzyme genes among populations is important to identify risk groups for adverse drug reaction and to select representative populations for clinical trials. Although India emerged as an important hub for clinical trials, information about the pharmacogenetic diversity for this region is still lacking. Here, we investigated genetic diversity of cytochrome-P450-2C9 (CYP2C9) gene which metabolizes wide range of drugs and is highly expressed in the human liver. Methods: In total, 1278 individuals from 36 diverse Indian populations, 210 individuals from in-house data-repository and 489 other South Asian samples from the 1000 Genomes Project were selected. Variants observed in CYP2C9 gene were subjected to various statistical analyses. Results: High frequency of CYP2C9*3 (∼ 13%) and CYP2C9*3/*3 (∼ 1%) was observed among South Asians, compared to 21 populations living outside the Indian subcontinent. The allelic/genotypic frequency does not correlate with geographical location or linguistic affiliation, except populations speaking Tibeto-Burmans language, who have lower frequency of CYP2C9*3 and CYP2C9*3/*3. Since, South Asians practice strict endogamy, presence of unique mutation and high frequency of homozygous genotypes not surprising. CYP2C9*3 has been associated with therapeutic response.The effect of CYP2C9*3/*3 is more pronounced compared to heterozygous and wild type homozygous genotypes as evident in many in vitro studies. As South Asians have high frequency, it would be interesting to explore potential of CYP2C9*3 as a marker for personalized therapy. Our study revealed several rare functional variants, which form eight novel and rare haplotypes of CYP2C9 (CYP2C9*63–*70). Of which, CYP2C9*64, *65, *66, *68, *69 and *70 haplotypes are South Asian-specific. Conclusion: Overall, we find high genetic heterogeneity within South Asians and identified South Asian-specific putative functional CYP2C9 haplotypes. High frequency of CYP2C9*3 and CYP2C9*3/*3 was observed in South Asian populations. Taken together, current study greatly enriches the knowledge of naturally occurring CYP2C9 variants and its diversity in South Asia, which are relevant to further CYP2C9-related functional research and for personalized medicine.Keywords
This publication has 24 references indexed in Scilit:
- Genetic Epidemiology of Pharmacogenetic Variations in CYP2C9 , CYP4F2 and VKORC1 Genes Associated with Warfarin Dosage in the Indian PopulationPharmacogenomics, 2014
- CYP2C9 polymorphism analysis in Han Chinese populations: building the largest allele frequency databaseThe Pharmacogenomics Journal, 2013
- Distribution of CYP2C9*13 allele in the Chinese Han and the long‐range haplotype containing CYP2C9*13 and CYP2C19*2Biopharmaceutics & Drug Disposition, 2012
- Reconstructing Indian population historyNature, 2009
- The Role of Ethnicity in Variability in Response to Drugs: Focus on Clinical Pharmacology StudiesClinical Pharmacology & Therapeutics, 2008
- Influence of the CYP2C9 AND CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India.2006
- Identification of a null allele of CYP2C9 in an African–American exhibiting toxicity to phenytoinPharmacogenetics, 2001
- Genetic Polymorphism of Cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese PopulationTherapeutic Drug Monitoring, 1998
- Cytochrome P4502C9: an enzyme of major importance in human drug metabolismBritish Journal of Clinical Pharmacology, 1998
- The role of the CFP2C9-Leu 359 allelic variant in the tolbutamide polymorphismPharmacogenetics, 1996